Floatz logo

DABIGATRAN ETEXILATE

Secondary Prevention

Boehringer IngelheimSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Secondary Prevention cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Sichuan Provincial People's Hospital
Phase 4BBB
Plavix
Sichuan Provincial People's Hospital
Phase 4BB
Ezetimibe
Seoul National University Hospital
N/AD

Same molecule, other indications

DABIGATRAN ETEXILATE is also rated in:

atrial fibrillationDormant
BB
Indicative ·
67 / 100
View asset →
type 2 diabetes mellitusDormant
BB
Indicative ·
65 / 100
View asset →
chronic kidney diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →